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Introduction
Chronic atypical neutrophilic dermatosis with lipodystro-
phy and elevated temperature (CANDLE) syndrome is a
newly described autoinflammatory disease, which had
been recently reported in 9 patients. It is characterized by
onset during the first year of life of recurrent fevers, pur-
puric skin lesions, arthralgia, progressive lipodystrophy,
hypochromic or normocytic anemia, delayed physical
development and increased levels of acute phase
reactants.
Case Report
A 10 year-old young girl presented at 10 months of age
with recurrent fevers, hepato-splenomegaly and nodular
erythematous skin lesions of trunk and limbs; subse-
quently she progressively developed lypodistrophy,
arthralgia and arthritis and edema of eyelids. She started
steroids and, then, cyclosporine with partial benefit and
with recurrence of symptoms following tapering and/or
discontinuation. Her weight and height were below the
5th percentiles with partial growth hormone defect. Skin
biopsy showed typical features of lobular panniculitis.
Laboratory tests showed persistent elevated acute phase
reactants and Serum amyloid A levels persistent chronic
anemia, mild recurrent leucopenia (minimum neutrophil
count 1040), thrombocytopenia (minimum 94.000) and
decreased IgA, IgG and IgM levels.Immunological and
cytogenetic studies performed on bone marrow were
normal. Response to hydroxychlorochine or colchicine
was unsatisfactory. Subsequently, the patient developed
severe proteinuria. Renal biopsy revealed a minimal
change glomerulopathy; she was started on a standard
nephrotic syndrome high-dose steroid protocol with remis-
sion of proteinuria.Complete sequencing of TNFRSF1A
and MVK genes showed no mutations. Molecular analysis
of PSMB8 (proteasome subunit b type 8) gene revealed the
presence of c.208A>T p.(Thr70Ser) variant in heterozygotic
status that has never been reported before. Because of a
persistent inflammatory state, she was started on daily ther-
apy with Anakinra (2 mg/Kg/die), discontinued after 10
days for absence of response. She is currently managed
with chronic low dose glucocorticoids.
Discussion
The similarities in the clinical phenotype of this case with
those described by Liu et al support the conclusion that
this novel variant Thr70Ser in the PSMB8 gene is a causa-
tive mutation. Minimal change glomerulopathy has not
been reported in CANDLE patients. It may be a casual
association: however, one of the 9 original patients is
described as having nephrotic syndrome. Our patient also
did not respond to Anakinra. A better understanding of
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